Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbbVie Inc (ABBV) vs Bank of Nova Scotia (BNS) Price & Performance

AbbVie IncTrade
Bank of Nova ScotiaTrade

Price performance (Past 24H)

Key statistics

AbbVie Inc vs Bank of Nova Scotia — how do they compare? AbbVie Inc trades at $249.26 (market cap $441.94B), while Bank of Nova Scotia trades at $89.92 (market cap $108.32B). The key difference: AbbVie Inc is far larger — about 4.1× Bank of Nova Scotia's market cap, and Bank of Nova Scotia pays the higher dividend (3.64%). Which is the better fit depends on your goals.

ABBVBNS
Market Cap
$441.94B$108.32B
Sector
HealthFinancials
52-Week High
$263.58$90.29
52-Week Low
$197.38$56.41
Enterprise Value
$506.19B
Dividend Yield
2.77%3.64%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbbVie Inc

AbbVie (ABBV) trades at $247.91, up 0.76% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 70.73% buy consensus highlight robust fundamentals, driven by Skyrizi and Rinvoq growth offsetting Humira declines. Positive news includes Phase 2 ovarian cancer data and institutional stake increases, reinforcing momentum.

Outlook remains positive with a $278.69 price target, though risks include patent cliffs and debt levels. Revenue growth and dividend stability offer appeal, but investors should monitor competitive pressures and regulatory developments for sustained performance.

Bank of Nova Scotia

Bank of Nova Scotia (BNS) trades at $88.56, down 0.33% on the day. The stock exhibits a bullish technical trend with strong analyst support, evidenced by a 'Buy' consensus from 53% of covering analysts. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $1.47 surpassing the $1.42 estimate. The company maintains a solid net income margin of 24.86% and recently announced a dividend of $1.14 per share, highlighting its commitment to shareholder returns.

The outlook for BNS is positive, supported by earnings momentum, a diversified banking model, and an attractive dividend. Key risks include exposure to macroeconomic volatility and competitive pressures in the banking sector. The current valuation, with a P/E of 17.1, appears reasonable relative to its profitability and growth prospects.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbbVie Inc

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

Read more on ABBV

About Bank of Nova Scotia

Bank of Nova Scotia is a global financial services provider. The bank has five business segments: Canadian banking, international banking, global wealth management, global banking and markets, and other. It offers a range of advice, products, and services, including personal and commercial banking, wealth management and private banking, corporate and investment banking, and capital markets. The bank's international operations span numerous countries and are more concentrated in Central and South America.

Read more on BNS